Transducing agonist binding to channel gating involves different interactions in 5-HT3 and GABAC receptors.
5-hydroxytryptamine (5-HT)3 and gamma-aminobutyric acid, type C (GABAC) receptors are members of the Cys-loop superfamily of neurotransmitter receptors, which also includes nicotinic acetylcholine, GABAA, and glycine receptors. The details of how agonist binding to these receptors results in channel opening is not fully understood but is known to involve charged residues at the extracellular/transmembrane interface. Here we have examined the roles of such residues in 5-HT3 and GABAC receptors. Charge reversal experiments combined with data from activation by the partial agonist beta-alanine show that in GABAC receptors there is a salt bridge between Glu-92 (in loop 2) and Arg-258 (in the pre-M1 region), which is involved in receptor gating. The equivalent residues in the 5-HT3 receptor are important for receptor expression, but charge reversal experiments do not restore function, indicating that there is not a salt bridge here. There is, however, an interaction between Glu-215 (loop 9) and Arg-246 (pre-M1) in the 5-HT3 receptor, although the coupling energy determined from mutant cycle analysis is lower than might be expected for a salt bridge. Overall the data show that charged residues at the extracellular/transmembrane domain interfaces in 5-HT3 and GABAC receptors are important and that specific, but not equivalent, molecular interactions between them are involved in the gating process. Thus, we propose that the molecular details of interactions in the transduction pathway between the binding site and the pore can differ between different Cys-loop receptors.
Price
Kerry L
KL
Department of Biochemistry, University of Cambridge and Neurobiology Division, MRC-LMB, Hills Rd., Cambridge CB2 2QH, United Kingdom.
Millen
Katherine S
KS
Lummis
Sarah C R
SC
D019943:Amino Acid Substitution; D000818:Animals; D001665:Binding Sites / Q000235:genetics; D015870:Gene Expression; D006801:Humans; D015640:Ion Channel Gating / Q000187:drug effects / Q000502:physiology*; D017433:Protein Structure, Secondary / Q000235:genetics; D017434:Protein Structure, Tertiary / Q000235:genetics; D018079:Receptors, GABA / Q000235:genetics / Q000378:metabolism*; D011963:Receptors, GABA-A / Q000378:metabolism; D018009:Receptors, Glycine / Q000378:metabolism; D011978:Receptors, Nicotinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000235:genetics / Q000378:metabolism*; D017366:Serotonin Receptor Agonists / Q000378:metabolism / Q000494:pharmacology; D014981:Xenopus; D015091:beta-Alanine / Q000378:metabolism / Q000494:pharmacology
C087200:GABA-C receptor; D018079:Receptors, GABA; D011963:Receptors, GABA-A; D018009:Receptors, Glycine; D011978:Receptors, Nicotinic; D011985:Receptors, Serotonin; D017366:Serotonin Receptor Agonists; D015091:beta-Alanine